謝 名宗

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Endoscopic Hemostasis 62%
3. pembrolizumab 58%
4. Bismuth 57%
5. Nivolumab 56%
6. Choledocholithiasis 55%
7. Tranexamic Acid 54%
8. Sorafenib 50%
9. Endoscopic Retrograde Cholangiopancreatography 47%
10. Pylorus 46%
11. Amoxicillin 46%
12. Peptic Ulcer 44%
13. Helicobacter pylori 40%
14. Survival 33%
15. Metronidazole 33%
16. Therapeutics 28%
17. Tomography 28%
18. Anti-Bacterial Agents 27%
19. Drug Resistance 27%
20. Hemorrhage 26%
21. Drug Therapy 24%
22. Liver 21%
23. Treatment Failure 21%
24. Comorbidity 18%
25. Ulcer 16%
26. Protein-Tyrosine Kinases 16%
27. Levofloxacin 14%
28. Clarithromycin 14%
29. Thrombosis 10%
30. Safety 10%
31. Multivariate Analysis 10%
32. Powders 9%
33. Programmed Cell Death 1 Receptor 8%
34. Infections 8%
35. Odds Ratio 8%
36. Endoscopy 8%
37. Tetracycline Resistance 8%
38. Prospective Studies 7%
39. Breath Tests 7%
40. Costs and Cost Analysis 6%
41. Christianity 6%
42. Incidence 5%
43. Urea 5%
44. Duration of Therapy 5%
45. Clinical Trials 5%